Of note, pharmacological treatment with GLP-1/GIP in a mice model of MASH seemed to further reduce steatosis, inflammation, and potentially, fibrosis and liver dysfunction enzymes, as well as ameliorating lipid and glycemic profile, compared with GLP-1 and GIP mono-agonists. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.